Reduced renal function is associated with progression to AIDS but not with overall mortality in HIV-infected kenyan adults not initially requiring combination antiretroviral therapy

Table 2 Multivariable models showing the hazard ratios for the associations between enrolment creatinine clearance and times to meeting criteria for initiation of cART^a

	Hazard ratios (95% confidence intervals)
Enrolment characteristic	Model 1	Model 2 ^b
Creatinine clearance^c(mL/min)
≥60 (reference)	1.0	1.0
< 60	1.34 (1.23-1.52)^d	1.24 (1.11-1.39)^d
Age (per 10 year increase)	1.00 (0.95-1.05)	1.01 (0.96-1.07)
Male sex (compared with female sex)	1.22 (1.09-1.37)^e	1.27 (1.13-1.42)^d
WHO stage 2 (compared with stage 1)	1.34 (1.22-1.48)^d	1.30 (1.18-1.43)^d
CD4 cell count (per 50 cells/mm³ increase)	0.88 (0.87-0.90)^d	0.88 (0.87-0.90)^d
Haemoglobin (per 1 g/dL increase)	0.90 (0.88-0.92)^d	0.91 (0.89-0.93)^d
Weight (per 1 kg increase)		0.99 (0.98-0.99)^d

^aCombination antiretroviral therapy, defined as development of either CD4 cell count < 200 cells/mm³ or WHO disease stage 3 or 4
^bModel 1 adjusted for weight
^cEstimated using the Cockcroft-Gault equation
^dP < 0.0001
^eP < 0.001